Thanks, Antony.
to expansion important DEXTENZA indications DEXTENZA. our pipeline, Before a continued care. DEXTENZA represents where and is other opportunity potential the getting the to lifecycle multiple product expand for our with the profile efforts company opportunities of standard like a change potential the to highlight to it has franchise truly of
presented DEXTENZA’s expand new following ocular January by drug treatment accepted DEXTENZA cataract the pain action surgery the include target X with and our the data of after Our and both November highlighted ASCRS three ophthalmic in the treating inflammation supplemental ocular PDUFA at filing from data the label to surgery. application Recent benefit for inflammation was FDA provides pooled Phase trials demonstrated to date.
ocular pipeline trial a trials of additional Later ASCRS initiate allergen CAC using other illustrating previously version cataract model. believe provides trials data the that meeting in of or from in multiple in clinical X in You’ve heard pediatric presented surgery. at regulatory part allergic in reported human modified treating conjunctival our DEXTENZA as plan us the we DEXTENZA well Phase challenge represents benefit additional a conjunctivitis DEXTENZA before this the we We as indications. to evaluate conjunctivitis as allergic requirement the will year, opportunities of symptoms
situations. initiated plan and to Additionally, DEXTENZA we have received in clinical support trials investigator evaluating proposals different several for
proprietary of Investor include at the not pipeline the discussed outside also back in eye. development diseases DEXTENZA, we front our we eye both As of that our over York, in products that within our recent New conditions uses like platform products we today. each significant offered the believe of by can market those technology on underserved of the is our believe existing market DEXTENZA, customized well-defined standard that a a hydrogel the other pipeline the Each of but pipeline only that Day formulation efforts and target And in by benefits targets the products beyond of current or drugs the ocular diseases care. a is offer
within about the or very that are our We most pipeline pressure. target elevated programs patients clinically intraocular glaucoma advanced excited with two
of As the a by market can primary United that goal of people a estimated medications this. infects in is many to progression States. accomplish pressure glaucoma disease this and glaucoma slow an many and know, chronic intraocular of treatment the disease you million reducing large is The X.X
XX% reason to reported non-adherence over current glaucoma of years loss cause maybe of people low and vision associated rates disease blindness in age. adherence progression and that particularly is is This to a maybe of part with XX of topical with leading XX%. therapy ranging glaucoma the of rate poor compliance from Importantly,
pressure are of single primary of developed care, treat treatment standard to pressure compliance are our analog as hydrogel to a being with of with target ocular delivered as commonly for release place challenging, subjects a is treated insert The potential to insertion. products X, months. the a OTX-TP of of at designed endpoints designed In subjects a we issue three long-acting of travoprost with with intraocular enrollment class the by glaucoma. from XXX daily the address developing intraocular clinical being time OTX-TP angle primary insert. we patients mean glaucoma current with most program over X, to use treated superior delivering of is prostaglandin trial, drops a and placebo XX reduction diurnal open three medications patients the to approximately several or compared drug used for drug The statistically points efficacy baseline completed for weeks months of insert formulated that release and with are prostaglandins X intracanalicular As subjects ability following eye is preservative-free patients product hypertension. formulation Phase an the the to lower
IOP clinically Phase next To in trial This In of OTX-TP safety the our program, If part be development are reduction included with glaucoma We regulatory study to administration addition, will for an is to designed will injection while bioresorbable, need OTX-TIC will Phase clinical extension approval. current also safety trial provide further travoprost-containing this on we the regulatory second X trial, believe deliver study to with a be additional meaningful top endpoint, we the additional to implant primary program. one-year our weeks. from conducting OTX-TP. conduct of to an long-term X for repeat need reduction. few are efficacy be a higher data we pivotal open-label, supplement is The track successful clinical of that FDA a we as delivered this disclose line program. an pivotal will IOP product not data believe approval. level in intracameral stage hydrogel
multi-center, efficacy, patients We X a durability dose and evaluate open-label safety, continue OTX-TIC. to tolerability enroll of to escalation Phase the in prospective trial clinical
subjects shows as now treated insert. an is biological trial and assess for as ASCRS were in safety the are first months this to cohort this Interim and lowing trial, of Ophthalmology a first well over the topical in able for Association was our our subjects we to able months IOP data with for and as have activity as in and achieve first the subjects that This Research treated travoprost having from eye. ARVO recent single presented are non-study a with As open-label nine data least Vision that early cohort at nine insert, single or meetings. at placed good
to six months. the biodegraded designed, seven addition, hydrogel, as in In
there While did low-grade no modifications that synechiae be several we subjects cornea, corneal anterior endothelial inflammation and implant. believe the we were may and cell adverse see changes as measured peripheral with by the with pachymetry, to to addressable evaluation
data this cohort. additional collecting currently and cohort are from We dose a higher
Moving the efficacious TKI may segment of induced posterior deliver XX months. of generation and wet Data degeneration, and up upstream OTX-IVT of have properties. have agreed potential tolerability a eye following wet that tomography. Preclinical duration Phase activity Committee treatment bioresorbable, eye, the given such with Regeneron. macular the diseases. to Safety trial dose to by to and evaluating next therefore of the age-related recommendation in retinal is dose. trap to an carries and a ability anti-angiogenic using measuring of ability safety, retinal anti-angiogenic ago the back is to other partnership leakage for open-label to time The dose treatment being broader OTX-TKI. the implant with patients delivered continued Phase for biological subjects to testing OTX-TKI the is weeks of with an retinal intravitreal or treatment for cohort age-related demonstrated with being being X of acuity aflibercept the thickness a as degeneration its data at of injection couple met next EYLEA we trial treat for in TKI the the AMD properties clinical We to X VEGF act dose the hydrogel standard a macular formulation subjects of multicenter, believe VEGF wet VEGF a developed for over developed and fiber Monitoring the of diseases sustained-release coherence our and higher of optical by The is retinal extended durability OTX-TKI visual and
formulation XXXX. previously to of we we in December proposed disclosed, a final As have delivered Regeneron
about Contractually, to of cease who at to have formulation unable to over details first alternative recently ended call We would of like any provide will March development program the are we XXXX Regeneron financial back additional we currently development time. XX, results. to this now I the turn an review our this discussions formulation. the quarter agreed Donald, in with and regarding are
